Cargando…

In Vitro Skin Retention of Crisaborole after Topical Application

Crisaborole, a nonsteroidal phosphodiesterase 4 inhibitor, represents the first nonsteroidal medication approved for the treatment of atopic dermatitis in over a decade. In this work, crisaborole skin permeation and retention was studied in vitro from a 2% ointment using porcine skin as barrier. Cri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fantini, Adriana, Demurtas, Anna, Nicoli, Sara, Padula, Cristina, Pescina, Silvia, Santi, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355453/ https://www.ncbi.nlm.nih.gov/pubmed/32481663 http://dx.doi.org/10.3390/pharmaceutics12060491

Ejemplares similares

The Influence of Formulation and Excipients on Propranolol Skin Permeation and Retention
por: Padula, Cristina, et al.
Publicado: (2018)

Buccal Permeation of Polysaccharide High Molecular Weight Compounds: Effect of Chemical Permeation Enhancers
por: Fantini, Adriana, et al.
Publicado: (2022)

New Insights on the Mechanism of Fatty Acids as Buccal Permeation Enhancers
por: Padula, Cristina, et al.
Publicado: (2018)

An Alternative Device for the Topical Treatment of Oral Cancer: Development and Ex-Vivo Evaluation of Imiquimod-Loaded Polysaccharides Formulations
por: Remiro, Paula de Freitas Rosa, et al.
Publicado: (2022)

Ex Vivo Conjunctival Retention and Transconjunctival Transport of Poorly Soluble Drugs Using Polymeric Micelles
por: Pescina, Silvia, et al.
Publicado: (2019)

Improvement of Imiquimod Solubilization and Skin Retention via TPGS Micelles: Exploiting the Co-Solubilizing Effect of Oleic Acid
por: Ghezzi, Martina, et al.
Publicado: (2021)

Preliminary Investigation on Simvastatin-Loaded Polymeric Micelles in View of the Treatment of the Back of the Eye
por: Pescina, Silvia, et al.
Publicado: (2021)

Synthesis and Ex Vivo Trans-Corneal Permeation of Penetratin Analogues as Ophthalmic Carriers: Preliminary Results
por: Pescina, Silvia, et al.
Publicado: (2020)

Nanostructured Lipid Carriers for Enhanced Transscleral Delivery of Dexamethasone Acetate: Development, Ex Vivo Characterization and Multiphoton Microscopy Studies
por: González-Fernández, Felipe M., et al.
Publicado: (2023)

Crisaborole for atopic dermatitis
Publicado: (2019)

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis
por: Purohit, Vivek, et al.
Publicado: (2020)

Repigmentation in a patient with vitiligo on crisaborole 2% ointment
por: Tam, Idy, et al.
Publicado: (2021)

Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers
por: Zane, Lee T., et al.
Publicado: (2016)

Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia
por: Li, Lijun
Publicado: (2023)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

New Strategies for Improving Budesonide Skin Retention
por: Padula, Cristina, et al.
Publicado: (2021)

Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation
por: González-Fernández, Felipe M., et al.
Publicado: (2021)

Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting
por: Sonvico, Fabio, et al.
Publicado: (2018)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
por: SILVERBERG, Jonathan I., et al.
Publicado: (2020)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Crisaborole Loaded Nanoemulsion Based Chitosan Gel: Formulation, Physicochemical Characterization and Wound Healing Studies
por: Ansari, Mohd Nazam, et al.
Publicado: (2022)

Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis
por: PAVLENKO, Darya, et al.
Publicado: (2023)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

In Vivo Assessment of Clobetasol Propionate-Loaded Lecithin-Chitosan Nanoparticles for Skin Delivery
por: Şenyiğit, Taner, et al.
Publicado: (2016)

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study
por: Zane, Lee T., et al.
Publicado: (2016)

Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions
por: Moreno, Esther, et al.
Publicado: (2019)

Pentapeptide modified ethosomes for enhanced skin retention and topical efficacy activity of indomethacin
por: Niu, Jiangxiu, et al.
Publicado: (2022)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Knuckle Pads Successfully Treated with 2% Crisaborole Ointment Combined with Triamcinolone Acetonide and Neomycin Plaster: A Case Report
por: Liang, Yimin, et al.
Publicado: (2023)

The Skin and Natural Cannabinoids–Topical and Transdermal Applications
por: Filipiuc, Silviu-Iulian, et al.
Publicado: (2023)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Characteristics of Atopic Dermatitis Patients Treated with Crisaborole: Real-World Data from a Large Healthcare Provider Database in Israel
por: Weil, Clara, et al.
Publicado: (2022)

Improvement of a Three-Layered in vitro Skin Model for Topical Application of Irritating Substances
por: Schmidt, Freia F., et al.
Publicado: (2020)

In vitro assessment of skin sensitization, irritability and toxicity of bacteriocins and reuterin for possible topical applications
por: Soltani, Samira, et al.
Publicado: (2022)

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

In Vitro Enhanced Skin Permeation and Retention of Imiquimod Loaded in β-Cyclodextrin Nanosponge Hydrogel
por: Argenziano, Monica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9oa72oaqmhnold12vl2pvlcagi